• Earlier this week, Abbott Laboratories received FDA De Novo authorization for its Libre Duo 10 Day system, a first-of-its-kind wearable that continuously monitors both glucose and ketone levels in people with diabetes aged 2 and older, with a U.S. launch planned later this year and integration into major insulin pump ecosystems.
• This dual glucose‑ketone sensor introduces a new integrated continuous glucose and ketone monitoring standard in the U.S., potentially strengthening Abbott’s digital diabetes platform through real-time ketone tracking that may help identify rising risk of diabetic ketoacidosis without adding extra testing steps for patients.
• We’ll now explore how the Libre Duo 10 Day dual glucose‑ketone launch potential reshapes Abbott’s existing investment narrative around innovation and margins.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Abbott Laboratories Investment Narrative Recap

To own Abbott today, you need to believe in its diversified healthcare model and in continued uptake of its higher margin device and diagnostics platforms, especially FreeStyle Libre. The Libre Duo 10 Day authorization fits that story, but does not remove near term pressure from diagnostics headwinds, FX and tariff impacts, or ongoing litigation, which remains one of the more immediate overhangs on profitability and cash deployment.

Alongside Libre Duo, Abbott’s US$670 million agreements to resolve the Gill case and roughly 2,000 related NEC claims are highly relevant, because they crystallize a significant portion of legal exposure while still leaving a large docket of remaining cases that could influence future earnings and capital allocation decisions.

However, investors should be aware that litigation linked to infant nutrition and medical products could still...

Abbott Laboratories’ narrative projects $60.4 billion revenue and $9.5 billion earnings by 2029. This requires 9.0% yearly revenue growth and about a $4.1 billion earnings increase from $5.4 billion today.

Uncover how Abbott Laboratories' forecasts yield a $119.12 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community currently see Abbott’s fair value between about US$119 and US$152 per share, underlining how far opinions can spread. Set against that backdrop, the Libre Duo 10 Day launch as a higher value diabetes technology raises interesting questions about how product mix and pricing power might influence Abbott’s future earnings profile.

Explore 5 other fair value estimates on Abbott Laboratories - why the stock might be worth just $119.12!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Abbott Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Abbott Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Abbott Laboratories' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.